Alpha Teknova earnings date
Want to see TKNO full AI Analyst Report?
Alpha Teknova (TKNO) Q3 2026 Earnings Report
TKNO Q3 2026 EPS Results
- Actual EPS
- -$0.06
- Consensus EPS
- -$0.07
- Beat/Miss
- Beat by +$0.01
- One Year Ago EPS
- -$0.08
TKNO Q3 2026 Revenue Results
- Actual Revenue
- $12.70M
- Expected Revenue
- $11.71M
- Beat/Miss
- Beat by +$993.00K
- YoY Revenue Growth
- +21.52%
Earnings Announcement Details
- Quarter
- Q3 2026
- Date
- 11/04/2026
- Time
- After Close
- Conference Call
- Wednesday, November 4, 2026
Alpha Teknova's next earnings date is estimated for March 16, 2027, based on past reporting schedules.
Q3 2026 Earnings Call Audio
Q3 2026 Earnings Slide Deck
Q3 2026 Earnings Call Summary
The call was strongly constructive. Teknova reported record revenue, 22% year-over-year growth, an 86% increase in Clinical Solutions revenue, improved gross margin and reduced cash usage, while raising its 2026 revenue guidance and strengthening its balance sheet with a $46 million equity raise. The main challenges were continued weakness in early-stage biotech and catalog demand, ongoing operating losses and cash outflow, and the fact that the biotech recovery remains early and not yet fully established.
Teknova increased 2026 total revenue guidance to $46 million to $48 million, implying approximately 16% revenue growth at the midpoint compared to 2025; it expects gross margin to land in the mid-to-upper 30s percentage range for the full year 2026 and is still targeting mid-to-high 30s percentage for gross margin for the full year of 2026, with Q4 expected to be similar in the mid-to-high 30s, while sales and marketing spend is expected to be approximately $2 million for the full year 2026 and operating expenses are forecast to be at least $8 million in the fourth quarter of 2026. Each additional dollar of revenue is estimated to drop through at a marginal cash rate of approximately 70%, adjusted EBITDA is expected to become positive in the range of $52 million to $57 million in annualized revenue, and if end markets are stronger in 2027 and stepped-up commercial investments bear fruit as anticipated, the company should report a positive adjusted EBITDA quarter before the end of 2027; free cash outflow is expected to be similar in the fourth quarter to the $1.4 million reported in the third quarter and less than $8 million for the full year 2026, while 2027 revenue guidance will be provided with full year 2026 results.
- Second Consecutive Record Revenue QuarterThird-quarter 2026 revenue reached a company record and increased 22% year over year, marking the first time in more than four years that growth exceeded 20%.
- Strong Custom Product DemandAbove-market growth came from custom products sold to life science tools, diagnostics and biopharma customers. Custom order line items increased approximately 30% year to date, and the customer base expanded by nearly 10%.
- Clinical Solutions Revenue SurgeClinical Solutions revenue was $3.2 million, up 86% from $1.7 million in the third quarter of 2025. The increase was attributed primarily to higher average revenue per customer and, to a lesser extent, more customers.
- Lab Essentials Revenue GrowthLab Essentials revenue was $9.0 million, up 9% from $8.3 million in the third quarter of 2025, driven by an increased number of customers and, to a lesser extent, higher average revenue per customer.
- Broad-Based Biopharma Custom DemandThe company reported a significant uptick in custom product purchases from biopharma customers, including programs already in clinical trials. Demand was broad-based across multiple accounts and therapeutic modalities, including monoclonal antibodies, oligo therapeutics and cell and gene therapy, with related specialty CDMO demand also increasing.
- Biotech Funding TailwindManagement said multiple sources report biotech funding was up approximately 70% on a trailing 12-month basis, with the company beginning to see the impact in higher custom product sales to biopharma customers after four consecutive quarters of significant year-over-year funding increases.
- Tools and Diagnostics Demand Remains RobustCustom product demand remained strong from tools and diagnostics customers, particularly in liquid biopsy, sequencing and spatial biology applications. The majority of customers making a material impact were existing customers that are scaling their purchases.
- Gross Profit and Gross Margin ImprovementThird-quarter gross profit increased to $4.8 million from $3.2 million a year earlier. Gross margin expanded to 38.0% from 30.7%, primarily due to higher revenue and, to a lesser extent, lower fixed-cost absorption into cost of goods sold from changes in finished-goods inventory levels.
- Improved Net Loss and Adjusted EBITDANet loss improved to $3.5 million, or negative $0.06 per diluted share, from $4.3 million, or negative $0.08 per diluted share. Adjusted EBITDA improved to negative $1.0 million from negative $1.6 million.
- Lower Cash Usage and Capital ExpendituresFree cash outflow declined to $1.4 million from $2.4 million in the prior-year quarter, primarily due to lower cash used in operating activities. Capital expenditures decreased to $0.1 million from $0.4 million.
- Successful $46 Million Equity RaiseIn mid-October, Teknova completed an equity capital raise of $46 million with net proceeds of approximately $43 million. Management said the transaction achieved its objectives of improving balance-sheet flexibility, strengthening its negotiating position for potential tuck-in acquisitions and increasing the stock float for institutional investors.
- Raised 2026 Revenue GuidanceThe company increased its 2026 total revenue guidance to $46 million to $48 million. At the midpoint, the outlook implies approximately 16% revenue growth compared with 2025.
- Operating Leverage and Scalable InfrastructureApart from a planned $2 million annual increase in sales and marketing spending, operating expenses were flat year to date, while gross margins expanded by approximately 400 basis points. Management said prior investments in facilities, IT systems and manufacturing infrastructure are enabling the business to scale without a significant increase in expenses.
- Early Build-Tek TractionSince the new version of Build-Tek launched in June, customers from more than 100 organizations submitted more than 140 quote requests covering nearly 180 custom products. More than 40% of October requests came from returning customers, nearly every request involved a unique formulation, and approximately one-third were for RUO+ or GMP-grade products.
- Early Fill-Tek AdoptionSince its September introduction, Fill-Tek has generated many orders, with more than 60% quoted for GMP-grade products. The system allows customers to combine bag sizes and aseptic connectors into a single lot while reducing minimum order requirements and maintaining the company's stated turnaround times.
- Positive Longer-Term Clinical PipelineManagement expects some Clinical Solutions customers to increase purchase volumes as they move through clinical-trial phases and toward commercialization. At least one customer is expected to enter the commercial phase by 2027, with other customers continuing to advance through clinical development.
- Disciplined M&A StrategyTeknova remains focused on tuck-in acquisitions that can leverage its facilities, systems, manufacturing infrastructure and commercial channel. Potential areas include additional reagent manufacturing such as proteins, enzymes, antibodies, cytokines and growth factors, while management emphasized discipline around valuation, integration risks and targets that require substantial cash to operate.
- Path Toward Adjusted EBITDA ProfitabilityManagement expects adjusted EBITDA to become positive at annualized revenue of $52 million to $57 million. If end markets strengthen in 2027 and stepped-up commercial investments produce the anticipated results, the company expects to report a positive adjusted EBITDA quarter before the end of 2027.
- Full-Year Cash Outflow TargetThe company expects fourth-quarter free cash outflow to be similar to the third quarter and continues to anticipate full-year 2026 free cash outflow of less than $8 million.
TKNO Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Mar 16, 2027 | 2026 (Q4) | -0.08- | -0.09 | ― | ― |
| Nov 04, 2026 | 2026 (Q3) | -0.07-0.06 | -0.08 | 25.00% (+0.02) | |
| Aug 05, 2026 | 2026 (Q2) | -0.08-0.06 | -0.07 | 14.29% (+0.01) | |
| May 06, 2026 | 2026 (Q1) | -0.09-0.08 | -0.09 | 11.11% (+0.01) | |
| Feb 26, 2026 | 2025 (Q4) | -0.09-0.09 | -0.11 | 18.18% (+0.02) | |
| Nov 06, 2025 | 2025 (Q3) | -0.09-0.08 | -0.15 | 46.67% (+0.07) | |
| Aug 07, 2025 | 2025 (Q2) | -0.10-0.07 | -0.13 | 46.15% (+0.06) | |
| May 08, 2025 | 2025 (Q1) | -0.11-0.09 | -0.2 | 55.00% (+0.11) | |
| Mar 04, 2025 | 2024 (Q4) | -0.12-0.11 | -0.26 | 57.69% (+0.15) | |
| Nov 07, 2024 | 2024 (Q3) | -0.11-0.15 | -0.34 | 55.88% (+0.19) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
